Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.
Diabetes Dialogue: The Role of Nutrition in Diabetes Management, with Dawn Noe, RDN, LD
August 22nd 2023In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.
Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs
August 15th 2023In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.
Diabetes Dialogue: Latest News in Insulin Delivery, with Gary Scheiner, MS
July 11th 2023Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.
Diabetes Dialogue: Embracing Diabetes Tech and Social Media as a Clinician, with David Ahn, MD
July 7th 2023David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.
Diabetes Dialogue: Establishing Time in Range as a Primary Glucose Metric
July 6th 2023Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.
Diabetes Dialogue: "Second-Generation" Obesity Medications, with W. Timothy Garvey, MD
June 28th 2023W. Timothy Garvey, MD, sits down to discuss the results of SURMOUNT-2, the ongoing revolution of antiobesity medications, and why he is concerned over the growing prevalence of online weight loss clinics
Diabetes Dialogue: Improving Implementation of New Technology, with Cari Berget, RN, MPH
June 26th 2023Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.
Diabetes Dialogue: Managing & Addressing Mental Health Needs in Diabetes
June 25th 2023Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.
Diabetes Dialogue: Reforming Language in Metabolic Disease, with Jane Dickinson, RN, PhD
June 25th 2023At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.
Diabetes Dialogue: Diabetic Foot Ulcers and Social Determinants of Health
June 25th 2023At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.
Diabetes Dialogue: What to Know about the iLet Bionic Pancreas
May 26th 2023As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
Diabetes Dialogue: Breaking Down the Medtronic 780G Approval, with Robert Vigersky, MD
May 12th 2023In this episode, hosts sit down with Robert Vigersky, MD, chief medical officer of Medtronic Diabetes, for a discussion around the MiniMed 780G, including use, exclusive features, and how patients can obtain the new system.
Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D
May 3rd 2023In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
Diabetes Dialogue: News on Abbott Readers & CMS Expansion of CGM Availability
April 19th 2023Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss the implications of increased CGM access through a recent CMS expansion and take a deep dive into the latest Abbott news, including dispelling misconceptions surrounding the recall announcement.
Diabetes Dialogue: 10 Years of SGLT2s, Insulin for All, and Pemvidutide
March 29th 2023In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.
Diabetes Dialogue: CMS Expansion Ushers in New Age of CGM Access
March 17th 2023In this in-studio episode, hosts offer insight and perspective into what the news regarding the CMS expansion of CGM coverage means for people with diabetes and take a deep dive into a recent announcement of an FDA clearance for Abbott's FreeStyle Libre sensors.
Diabetes Community Reacts to Insulin Price Reduction by Eli Lilly and Company
March 2nd 2023After Eli Lilly and Company announced major reductions in list prices for multiple insulin products, the community rejoiced at the though of taking a major step forward toward equitable access to insulin. Learn more about the reaction from major organizations and those within the field.
Diabetes Dialogue: Practical Updates in Pediatric Diabetes, with Stuart Weinzimer, MD
March 2nd 2023In this episode, Stuart Weinzimer, MD sits down with hosts for a discussion on his research and experience with diabetes technology, the need to focus on patient-reported outcomes in pediatric diabetes, and strategies for meeting the practical needs of individuals with diabetes.
Diabetes Dialogue: Actualizing the Optimal Role of Inhaled Insulin, with Joanne Rinker, MS, RDN
February 28th 2023Hosts are joined by the associate director of Medical Affairs and Medical Education at MannKind for a special edition episode from ATTD 23 that focuses on use of inhaled insulin and future research plans for MannKind.
Diabetes Dialogue: Updates in Diabetes Management from ATTD 23, with Irl Hirsch, MD
February 26th 2023In this episode, Irl Hirsch, MD, discusses a study he is conducting examining skin changes associated with insulin pump use in people with type 1 diabetes. Later in the episode, Hirsch discusses what he is most excited about in terms of ongoing and future research in diabetes management.
Diabetes Dialogue: Screenings for Hearing Loss in Diabetes, with Joanne Rinker, MS, RDN
February 25th 2023In this episode from ATTD 2023, hosts are joined by Joanne Rinker, MS, RDN, who provides perspective on hearing loss in diabetes, including prevalence, the need for screening, and the underecognition of auditory issues in the midst of a growing population of people with diabetes.
Diabetes Dialogue: Mental Health and PRO Standardization, with Katharine Barnard-Kelly, PhD
February 25th 2023In this episode, hosts sit down with Katharine Barnard-Kelly, PhD, at ATTD 2023 to discuss the evolving recognition of the role of psychology in diabetes management for both pediatric and adult populations.
Diabetes Dialogue: Dexcom G7 and the Future of CGM, with Jake Leach
February 24th 2023At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.